Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Mar 13, 2008

Abbott, Genentech, Roche and OSI, Collaboration on Molecular Test for Lung Cancer Therapy Response

March 7, 2008 -Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer - Abbott (NYSE: ABT) announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva® (erlotinib), an oral tablet indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Under the agreement, Abbott will develop a test to detect extra copies of the epidermal growth factor receptor (EGFR) gene using its proprietary fluorescence in situ hybridization (FISH) technology in NSCLC... Abbott's Press Release -